Molecular Partners AG (MOLN) Q4 2024 Earnings Report

0 Followers

Previous Report: Q2 2024

Next Report: Q2 2025

CH:MOLN Q4 2024 EPS Results

Actual EPS-CHF0.30

Consensus EPS-CHF0.39

Beat/MissBeat by +CHF0.09

One Year Ago EPS-CHF0.60

CH:MOLN Q4 2024 Revenue Results

Actual RevenueCHF0.00

Expected RevenueCHF0.00

Beat/MissMet expectations

YoY Revenue Growth-100.00%

Earnings Announcement Details

QuarterQ4 2024

Date03/06/2025

TimeAfter Close

Conference CallThursday, March 6, 2025

CH:MOLN Upcoming Earnings

Molecular Partners AG's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q4 2024 Earnings Call Audio

CH:MOLN Q4 2024 Earnings Call

0:00 / 0:00

Q4 2024 Earnings Slide Deck

Q4 2024 Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 06, 2025|

% Change Since:

Earnings Call Sentiment|Positive

Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.

Company Guidance

During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.

Successful Execution of 2024 Program Goals

Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.

Positive Financial Health

The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.

Encouraging Clinical Results and Pipeline Progression

The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.

CH:MOLN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Mar 18, 2027	2026 (Q4)	- / -	-0.34	―
Aug 25, 2026	2026 (Q2)	-0.35 / -0.35	-0.55	36.36% (+0.20)
Mar 12, 2026	2025 (Q4)	-0.31 / -0.34	-0.305	-11.48% (-0.04)
Aug 25, 2025	2025 (Q2)	-0.39 / -0.55	-0.45	-22.22% (-0.10)
Mar 06, 2025	2024 (Q4)	-0.39 / -0.30	-0.602	49.34% (+0.30)
Aug 26, 2024	2024 (Q2)	- / -0.45	-0.9	50.00% (+0.45)
Mar 14, 2024	2023 (Q4)	-0.97 / -0.60	-0.99	39.19% (+0.39)
Aug 24, 2023	2023 (Q2)	-0.90 / -0.90	4.72	-119.07% (-5.62)
Mar 09, 2023	2022 (Q4)	-0.90 / -0.99	-0.94	-5.32% (-0.05)
Aug 25, 2022	2022 (Q2)	3.36 / 4.72	-1.02	562.75% (+5.74)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed